Combination of cGMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration

Eleonora Vighi1,2, Dragana Trifunovic1,3, Patricia Veiga-Crespo3,4, Andreas Rentsch2,6, Dorit Hoffmann1,2, Ayse Sahaboglu1,2, Torsten Strasser1,2, Manoj Kulkarni5,6, Eveline Bertolotti7, Angelique van den Heuvel1, Tobias Peters1, Arie Reijerkerk1, Thomas Euler1,2, Marius Ueffing5, Frank Schwede4, Hans-Gottfried Genieser4, Pieter Gaillard4,9, Valeria Marigo3,7, Per Ekström3,7, and François Paquet-Durand1,2

1 Dipartimento di Scienze della Vita, Università degli Studi di Modena e Reggio Emilia, 41125 Modena, Italy; 2 Forschungsinstitut für Augenheilkunde, Department für Augenheilkunde, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany; 3 Ophthalmology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, 22184 Lund, Sweden; 4 BIOLOG Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH, 28199 Bremen, Germany; 5 Centre for Integrative Neuroscience, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany; 6 Centre for the Treatment of Retinal Disease, Eye and Vision Research Institute, University of California, Los Angeles, California; 7 Department für Augenheilkunde, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany; 8 P2-BBB Medicines BV, 2333 CH Leiden, The Netherlands; and 9 Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium

Edited by Jeremy Nathans, Johns Hopkins University, Baltimore, MD, and approved February 2, 2018 (received for review October 30, 2017)

Inherited retinal degeneration (RD) is a devastating and currently untreatable neurodegenerative condition that leads to loss of photoreceptor cells and blindness. The vast genetic heterogeneity of RD, the lack of “druggable” targets, and the access-limiting blood–retinal barrier (BRB) present major hurdles toward effective therapy development. Here, we address these challenges (i) by targeting the cGMP (cyclic guanosine-3′,5′-monophosphate) signaling, a disease driver common to different types of RD, and (ii) by combining inhibitory cGMP analogs with a nanosized liposomal drug delivery system designed to facilitate transport across the BRB. Based on a screen of several cGMP analogs we identified an inhibitory cGMP analog that interferes with activation of photoreceptor cell death pathways. Moreover, we found liposomal encapsulation of the analog to achieve efficient drug targeting to the neuroretina. This pharmacological treatment markedly preserved in vivo retinal function and counteracted photoreceptor degeneration in three different in vivo RD models. Taken together, we show that a defined class of compounds for RD treatment in combination with an innovative drug delivery method may enable a single type of treatment to address genetically divergent RD-type diseases.

PKG | CNG channel | calpain | apoptosis | in vivo imaging

Hereditary retinal degeneration (RD) relates to a group of rare blinding diseases in which the photoreceptors of the retina degenerate and die. RD-type diseases, such as retinitis pigmentosa or Leber’s congenital amaurosis, are genetically very heterogeneous and, unfortunately, still untreatable (1, 2). Typically, these diseases first affect rod photoreceptors, which mediate vision under dim-light conditions. Since human vision mostly depends on cone photoreceptors—responsible for high-resolution color vision in bright light—rod-mediated vision is less critical for humans, and indeed many RD patients notice the primary loss of rods only at an advanced disease stage. However, the loss of rods triggers the subsequent loss of cones, which then leads to complete blindness (3). Conversely, the preservation of rods should thus save cone-mediated vision (4).

cGMP (cyclic guanosine-3′,5′-monophosphate) is a key molecule for photoreceptor signal transduction and has two general cellular functions: cyclic nucleotide gated ion channels (CNGCs) and cGMP-dependent protein kinase (PKG) (5). In the transduction cycle, photoreceptor cGMP is degraded by phosphodiesterase-6 (PDE6) and accordingly a loss-of-function mutation in the rod-specific Pde6b gene causes an excessive accumulation of cGMP in rods, as seen for instance in the rd1 mouse model for RD (6, 7). This cGMP accumulation brings on rapid rod cell death and eventually secondary loss of cones (8).

Abnormally high levels of cGMP in photoreceptors are a common feature in several genetically different forms of RD (6, 7, 9–13). Moreover, the cGMP effector PKG is overactivated in mutant photoreceptors and experimental PKG activation alone is sufficient to cause photoreceptor death in WT retina (7). The second major cGMP effector, the CNGCs, play an integral role in phototransduction, as they enable the influx of Na+ and Ca2+ by linking the transduction cascade to changes in photoreceptor membrane potential. CNGC beta subunit deletion protects rd1 photoreceptors (14), suggesting that also CNGCs contribute to the disease progression. Here, the mechanism probably involves increased Ca2+ influx and subsequent activation of Ca2+-dependent calpain-type proteases (15), including proteolytic activation of apoptosis-inducing factor (AIF) (16). cGMP-dependent overactivation of PKG and CNGCs in photoreceptors

Significance

Development of treatments for hereditary degeneration of the retina (RD) is hampered by the vast genetic heterogeneity of this group of diseases and by the delivery of the drug to an organ protected by the blood–retina barrier. Here, we present an approach for the treatment of different types of RD, combining an innovative drug therapy with a liposomal system that facilitates drug delivery into the retina. Using different animal models of RD we show that this pharmacological treatment preserved both the viability of cells in the retina as well as retinal function. Thus, our study provides an avenue for the development of therapies for hereditary diseases which cause blindness, an unmet medical need.

Author contributions: F.S., H.-G.G., P.G., V.M., P.E., and F.P.-D. designed research; E.V., D.T., P.V.-C., D.H., A.S., T.S., M.K., E.B., A.v.d.H., A. Reijerkkerk, and F.S. performed research; E.V., D.T., P.V.-C., D.H., A.S., T.S., M.K., E.B., T.P., A. Reijerkkerk, T.E., P.G., V.M., P.E., and F.P.-D. analyzed data; and E.V., D.T., P.V.-C., A. Rentsch, T.S., M.K., T.P., T.E., M.U., F.S., H.-G.G., P.G., V.M., P.E., and F.P.-D. wrote the paper.

Conflict of interest statement: A. Rentsch, H.-G.G., P.G., V.M., P.E., and F.P.-D. have filed three patents on the synthesis and use of cGMP analogues (PCTWO2016/146669A1, PCT/EP2017/0066113, and PCT/EP2017/017859) and have obtained a European Medicine Agency orphan drug designation for the use of CN03 for the treatment of retinitis pigmentosa (EU/3/15/1462). H.-G.G., P.G., V.M., P.E., and F.P.-D. are shareholders of, or have other financial interest in, the company Mireca Medicines, which intends to forward clinical testing of CN03.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

E.V., D.T., and P.V.-C. contributed equally to this work.

A. Rentsch, D.H., and A.S. contributed equally to this work.

*To whom correspondence may be addressed. Email: valeria.marigo@unimore.it, Per.Ekstrom@med.lu.se, or francois.paquet-durand@uni-tuebingen.de.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1718792115/-/DCSupplemental.
may, thus, qualify as critical disease drivers, making them promising candidates for a targeted molecular intervention therapy for RD (17).

To address the “targetability” of PKG and CNGC we have produced and tested cGMP analogs that inhibit these proteins. We devised a multilevel approach, in which cGMP analogs were designed, synthesized, and then screened in biological systems of increasing complexity. We first investigated cGMP analog effects in photoreceptor-like cells in vitro, then in organotypic retinal explant cultures and acute retinal slice preparations, and finally in vivo. In the living animal, the photoreceptor cells reside behind the blood–retinal barrier (BRB) (18). To overcome this barrier, a liposomal drug delivery vehicle was used, to facilitate transfer of cGMP analogs into the retina (19).

With this workflow, we identified a liposomal (LP) cGMP analog formulation, LP-CN03, which markedly preserved in vivo retinal function and reduced rod photoreceptor loss in three different RD models. Targeting cGMP signaling in this way not only protected rods affected by different causative mutations but also resulted in functional preservation of cones. In combination with liposomal delivery this approach offers a starting point for the development and translation of a pharmacological therapy with defined molecular targets.

Results

To investigate the potential of cGMP analogs as a new pharmacological class for the treatment of RD we took advantage of the possibilities to modify these compounds so that they could inhibit PKG and/or CNGC.

Development of cGMP Analogs. \( R_P \)-configured phosphorothioate-modified cGMP (\( R_P \)-cGMPS; SI Materials and Methods) analogs are classified as inhibitors of PKG, regardless of other nucleobase modifications (20, 21). The introduction of the \( \beta \)-phenyl-1,\( N^2 \)-etheno-modification (PET) onto the \( R_P \)-cGMPS backbone additionally inhibits photoreceptor CNGC (22). In contrast, \( R_P \)-cGMPS analogs with modifications in position 8 (C-8) alone are CNGC activators (23).

We used two parallel strategies for designing \( R_P \)-cGMPS analogs (Fig. 1A). First, we employed C-8 substituents either alone or in combination with the PET motif. Second, we evolved alternatives of the PET moiety, containing substituents that

![Fig. 1.](http://www.pnas.org/cgi/doi/10.1073/pnas.1718792115)

Vighi et al.
connect positions 1 and N² of the guanine nucleobase as well as substituents solely bound to position 1. These two strategies led to the generation of a set of R⁻cGMPS structures, most of them with strongly increased lipophilicity compared with the parent compound cGMP (Table 1).

To further improve potency and specificity, a strategy originally described for activatory cGMP-analogs (24) was extended to inhibitory cGMP analogs, where a polymer- (e.g., PEG) linked dimer with equal or different R⁻cGMPS analogs at its ends formed a so-called spanning clamp (Fig. 1A). Such inhibitory clamps are expected to simultaneously block two cGMP binding sites of CNGC or PKG by using a combination of PET- and 8-substituents with correspondingly slow off-rates after binding (24).

### Table 1. Lipophilicity data and putative effect of R⁻cGMPS analogs

| Compound          | Analog                                       | log k′ | log k′<sub>″</sub> | Effect on PKG | Effect on CNGC |
|-------------------|----------------------------------------------|--------|-------------------|---------------|----------------|
| A                 | cGMP                                         | 0.770  | 1.0               | +             | +              |
| B                 | R⁻-cGMPS                                     | 0.894  | 1.3               | –             | +              |
| C                 | R⁻-8-Br-cGMPS                                 | 1.285  | 3.3               | –             | –              |
| CN01              | B-pCPT-cGMPS                                 | 2.520  | 56                | +             | +              |
| CN02              | R⁻-8-pCPT-cGMPS                              | 2.610  | 69                | –             | +              |
| CN03              | R⁻-8-Br-PET-cGMPS                            | 2.831  | 115               | –             | –              |
| CN04              | R⁻-8-pCPT-PET-cGMPS                          | 3.530  | 575               | +<sup>†</sup> | +<sup>†</sup> |
| CN05              | R⁻-8-pHPT-PET-cGMPS                          | 3.078  | 203               | –<sup>†</sup> | –<sup>†</sup> |
| CN06              | R⁻-8-pIPrPT-PET-cGMPS                        | 3.815  | 1,109             | –<sup>†</sup> | –<sup>†</sup> |
| CN07              | R⁻-8-Br-(3-Tp)ET-cGMPS                       | 2.746  | 95                | –             | –              |
| CN08              | R⁻-8-oAPT-cGMPS                              | 1.974  | 16                | –             | +              |
| CN09              | R⁻-cGMPS-8-TMAmd-(EO)₈-EAmdMT-8-R⁻-cGMPS-PET  | 2.039  | 19                | –             | +              |
| CN10              | PET-R⁻-cGMPS-8-TMAmd-(EO)₈-EAmdMT-8-R⁻-cGMPS-PET | 3.236  | 292               | –             | ±<sup>†</sup> |

*<sup>+</sup>* indicates PKG/CNGC activator; **<sup>−</sup>** indicates inhibitor.

*Relative lipophilicity of R⁻-cGMPS analog compared with cGMP.

<sup>†</sup>No distinct assignment as CNGC inhibitor, as large substituents in 8 position tend to activate CNGC and might overrule inhibition induced by PET or PET-like substitution.

<sup>‡</sup>Values for dimeric analogs are not directly comparable with values for monomeric analogs.

---

Fig. 2. Screening of cGMP analogs in vivo. cGMP analogs were tested in retinal neurosphere-derived rod photoreceptor-like cell cultures (A–E) and organotypic retinal explant cultures (F and G). NT, not treated. (A) rd1 mutant photoreceptor-like cell cultures treated with 50 μM of the respective compound until DIV11 (red, ethidium homodimer staining; blue, nuclear counter staining). (B) Percentage of ethidium homodimer-labeled, dying photoreceptor-like cells [green, WT; red, rd1; yellow, different analog treatments; n = 5–62 cell culture samples obtained from two to seven independent preparations; red asterisks indicate toxic effect (i.e., more dying cells compared with NT)]. (C and D) Dose–response curves for CN02–CN07 starting at attomolar concentration. (E) EC₅₀ values for CN02–CN07 calculated from dose–response curves. (F) TUNEL assay (red) on vertical sections from P11 retinal cultures NT or treated with 50 μM of the respective compound. (G) Ratio (treated/NT) of TUNEL-labeled cells (same color code as in B, WT, n = 9 separate retinal explant cultures; rd1: NT, 22; CN02, 8; CN03, 8; CN04, 8; CN05, 6; CN06, 4; CN07, 8). Error bars: SEM. Statistical comparisons: B and G, NT-<sup>rd1</sup> vs. treated <sup>rd1</sup> using one-way ANOVA with Holm–Sidak’s multiple-comparisons test; ONL, outer nuclear layer containing rod and cone photoreceptor nuclei. (Scale bars: A, 100 μm; F, 50 μm.) *<sup>+</sup>P ≤ 0.05, **<sup>−</sup>P ≤ 0.01, ***<sup>++</sup>P ≤ 0.001.
Ten cyclic nucleotides were generated and denominated CN01–CN10. Previous work (20–22) had established the R4 oxo-substituted compound CN01 as a PKG and CNGC activator. The phosphorothioates CN02–CN10 were suggested to inhibit PKG. Compounds CN02, CN08, and CN09 were predicted to activate, and the remaining compounds to inhibit, CNGC. The absolute and relative lipophilicity was measured, and the compounds were grouped according to their structural motifs (PET and C-8) (20–22) and their predicted inhibitory patterns (Table 1) and then forwarded to testing in rod photoreceptor-like cell cultures as a prescreen for biological activity (Fig. 1B).

Screening of cGMP Analogs in Cell and Tissue Models for RD in Vitro. Primary rod photoreceptor-like cell cultures were derived from mice carrying the rd1 mutation in Pde6b (16). Here, cells expressing rhodopsin (i.e., rod photoreceptors) undergo spontaneous cell death, with a peak of cell demise at day in vitro (DIV) 11. Rhodopsin-expressing cells have functional CNGC (16, 25), display increased intracellular cGMP levels compared with WT cells, and express all three PKG isoforms (PKG1α, 1β, and 2; Fig. S1). We used these rd1 cell cultures as a rapid in vitro compound screening system by exposing them to different cGMP analogs and evaluating their effect on cell death at DIV11 using ethidium homodimer staining (Fig. 2 A and Fig. S2 A). For comparison, we tested CN01, the oxo-form of CN02 and activator of PKG and CNGC, which had no effect on cell death. In contrast, the R8-configurated sulfur forms (i.e., PKG inhibitors) CN02–CN07 showed significant protective effects at a concentration of 50 μM. At the same time CN08 and CN09 did not protect rd1 cells, while CN10 was toxic at 50 μM (Fig. 2 B). Dose–response curves were obtained for CN02–CN07 and we used to calculate the corresponding EC50 values (Fig. 2 C–E). Remarkably, compounds CN05 and CN07 maintained their protective effects on rd1 cells down to the pico- and even femtomolar range.
Compounds with significant protective activity on photoreceptor-like cells were validated in organotypic retinal explants. This system permits analysis of direct drug effects on photoreceptor viability while preserving their cytological context, under defined, serum-free conditions (7, 26). We used explants derived from rd1 mice (Fig. 2F), which show prominent rod degeneration at postnatal (P) day 11. The effects of CN02–CN07 on photoreceptor cell death were assessed at P11 using the TUNEL assay. The analysis gave the following rank order of protection: CN04 > CN03 > CN02 > CN05, with CN06 and CN07 having no discernible effect (Fig. 2G). The combined information from the cell and tissue levels led us with CN02–CN05 displaying significant photoreceptor neuroprotection.

CN02–CN05 were then tested with respect to inhibition of CNGCs and Ca²⁺ influx in cone photoreceptors. To this end, we used acute, freshly prepared retinal slices from WT animals expressing the ‘TN-XL’ Ca²⁺ biosensor exclusively in cones (27), monitored by a two-photon Ca²⁺ imaging approach (28) (Fig. 3A). Here, CN02, CN04, and CN05 significantly increased cone Ca²⁺ levels, suggesting CNGC activation. In contrast, CN03 moderately but significantly reduced cone Ca²⁺ levels, likely making it a weak inhibitor of CNGC (Fig. 3B and C).

Light-induced cone Ca²⁺ responses, as assessed by area under the curve and peak amplitudes, were increased by CN02, decreased by CN03, and remained essentially unchanged by CN04 and CN05 (Fig. 3D and E). Overall, these results imply that CN02 and CN03 kept the cone phototransduction cascade and light-induced cone responses largely intact. We later confirmed this interpretation by cone-specific electrotetrography (ERG) measurements (discussed below). Because long-term elevation of photoreceptor Ca²⁺ levels is thought to be deleterious (29–31), we selected CN03 as the compound for further investigations.

**CN03 Engages PKG and CNGC.** To investigate how CN03 exerted its positive effect on photoreceptor survival we analyzed molecular processes downstream of PKG and CNGC activation in rd1 photoreceptor-like cells (16). PKG phosphorylates target proteins, among them vasodilator-stimulated phosphoprotein (VASP) at the serine 239 residue (32). Increased phosphorylation at serine 239 was observed specifically in rhodopsin-expressing cells and cells undergoing cell death (Fig. S2 A and B). Ca²⁺-activated calpain-type proteases and the nuclear translocation of the calpain substrate and cell death effector AIF are important components of rd1 degeneration, likely downstream of CNGC activation (16, 33). In cells exposed to CN03 we found reduced serine 239 phosphorylation of VASP together with reduced Ca²⁺ levels (Fig. 4 A and B), suggesting PKG and CNGC inhibition. We confirmed that CN03 targeted PKG and not PKA by showing that VASP phosphorylation at serine 157, a PKA phosphorylation site, was not affected by the treatment (Fig. S2C). CN03 also decreased calpain activation (Fig. 4C) and nuclear localization of AIF (Fig. 4D).

**We neither observed signs of toxicity for CN03 at 50 μM on retinal explant cultures derived from WT animals (Fig. 4 A and E) nor on WT-derived photoreceptor-like cells at concentrations up to 500 μM (Fig. S3A and B).** rd1 explant cultures in vitro (Fig. S3C) and subsequent in vivo studies in rd10 animals (Fig. S3D) suggested 50 μM CN03 as a suitable treatment dose.

**CN03 Protects Photoreceptors Carrying Different Gene Mutations.** To assess the protective capacities of CN03 in forms of RD caused by different mutations in the same gene or in a different gene we extended our in vitro testing to retinal explant cultures derived from rd10 and rd2 mice. This is important, because the rd1 mutation in the Pde6b gene causes primary rod cell death already during retinal development, with over 50% rod cell loss by P18 (8, 34). In contrast, the rd10 mouse harbors a different Pde6b mutation, causing slower rod degeneration compared with rd1, with around 15% of the photoreceptor layer remaining at P30 (35). The rd2 (rds) mouse carries a mutation in the Ppah2 gene, leading to absence of rod and cone outer segments, with strongly reduced retinal function, but a relatively slow loss of both rods and cones. Around 35% of the rd2 photoreceptor layer is lost until P60 (36).

**Fig. 4.** CN03 acts on PKG and CNGC and reduces photoreceptor death in three different in vitro RD models. (A–D) Photoreceptor-like cell cultures derived from rd1 mice (NT, red bars) and effects of 50 μM CN03 (yellow bars) on degeneration markers (n = 9–15 cell cultures obtained from three to five independent preparations). (A) CN03 reduced the phosphorylation at serine 239 of the PKG-target VASP (pVASP, red). (B) Fluo-4, AM Ca²⁺ imaging (green, arrow indicates a cell with high Ca²⁺) indicated reduction in intracellular Ca²⁺. (C) Calpain protease activity assay brightly labeled condensed dying cells (arrows). Mean calpain labeling intensity was reduced after CN03 treatment. (D) AIF (red) translocation from mitochondria to nuclei (blue) and cell death, as assessed by the TUNEL assay (green), was restrained by CN03 treatment (triple-stained nuclei shown in white; see arrows). (E) CN03 (50 μM) had no adverse effects in P11 organotypic explants derived from WT (top row), rd1, rd2, and P18 rd10 explants CN03 reduced the number of dying cells in the ONL. (F) Quantification of the data from E; ratio (treated/NT) of TUNEL-labeled cells (NT WT, n = 2 separate retinal explant cultures; CN03 WT, 4; each NT mutant, 4; each CN03 treated mutant, 8; rd1 data from Fig. 2G shown for comparison). Error bars in A–D and F: SEM; Statistical comparisons: Student’s t test (unpaired, two-tailed). NT, not treated. (Scale bars: A–C, 50 μm; D, 20 μm; E, 50 μm).

Vighi et al.  |  PNAS Latest Articles  |  5 of 10
We found that CN03 protected photoreceptors in both rd2 and rd10 retinal explants in vitro (Fig. 4 E and F), thus generalizing our rd1 findings. Since rods outnumber cones 97:3 in the mouse retina (37), the protection observed in all three mutants is expected to relate mainly to a preservation of rods.

**Liposomal Formulation Facilitates Compound Delivery Across the BRB.** A major challenge for in vivo drug delivery to the retina is the BRB (18, 38). To facilitate retinal drug delivery, we chose glutathione-targeted PEGylated (GSH-PEG) liposomes, which had previously been shown to be a safe delivery system that

---

**Fig. 5.** CN03 liposomal formulation improves neuroprotective efficacy. (A) Electron microscopy of GSH-PEG liposomes loaded with CN03 showing a vesicle size of ~100 nm. (B) Neuroprotective effects of CN03 (yellow; EC50 = 400 ± 5 nM) and LP-CN03 (blue; EC50 = 3.5 ± 1 nM) in rd1 mutant photoreceptor-like cell cultures (n = 9 cell cultures from three independent preparations per concentration/treatment). (C) Cell death in NT rd1 photoreceptor-like cells (red bar), empty liposome treatment (LP, orange), coadministration of LP with free CN03 (LP+CN03, 1 µM; yellow/orange checkered), and LP-CN03 (1 µM), n = 8–62 different cell cultures from two to three independent preparations. (D) PK study in adult rats comparing in vivo half-life of free CN03 (10 min; yellow) vs. LP-CN03 (24 h; blue), n = 6 rats per group. (E) In vivo imaging using SLO. P10 WT mice were injected i.p. with carboxyfluorescein-loaded liposomes (LP-CF) and analyzed at P14. Fluorescent label was present mostly in retinal vasculature. (F) Cross-sections of P14 retinae from such LP-CF–treated animals displayed fluorescent labeling of choroidal blood vessels (chor.) but also of photoreceptors in ONL (G–I) Three different in vivo RD mouse models were treated with CN03 (yellow), LP only (orange), or LP-CN03 (blue), beginning at the onset of degeneration (P10, rd1; P14, rd2 and rd10; cf. Table S2). Photoreceptor survival was assessed on ex vivo retinal tissue sections by counting photoreceptor rows in ONL. WT (green) shown for comparison. n = 4–8 animals (one eye per animal) per time point and genotype. (G) Progression of photoreceptor degeneration in rd1 animals (red) compared with rd1 animals treated with free CN03 (yellow) and LP-CN03 (blue). (H) Progression of degeneration in NT vs. LP-CN03–treated rd2 mice. (I) Progression of degeneration in NT (red) or LP-treated (orange) or CN03-treated (yellow) vs. LP-CN03 treated (blue) rd10 animals. Note different y axis scales in G–I to account for different degeneration kinetics. Error bars: SEM. Statistical comparisons: C, one-way ANOVA and Newman–Keuls multiple comparison test; G–I, Student’s t test (unpaired, two-tailed). INL, inner nuclear layer; NT, not treated. (Scale bars: A, 100 nm; E, 200 µm; F, 25 µm.) *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.

---

We found that CN03 protected photoreceptors in both rd2 and rd10 retinal explants in vitro (Fig. 4 E and F), thus generalizing our rd1 findings. Since rods outnumber cones 97:3 in the mouse retina (37), the protection observed in all three mutants is expected to relate mainly to a preservation of rods.

Liposomal Formulation Facilitates Compound Delivery Across the BRB. A major challenge for in vivo drug delivery to the retina is the BRB (18, 38). To facilitate retinal drug delivery, we chose glutathione-targeted PEGylated (GSH-PEG) liposomes, which had previously been shown to be a safe delivery system that...
favors the transport of cargo across the blood–brain barrier after systemic administration (19, 39). We refer to GSH-PEG liposome-encapsulated CN03 as LP-CN03 (Fig. 5A). The protective capacity of this nanosized compound formulation was initially tested in rd1 photoreceptor-like cell cultures in vitro, where LP-CN03 (EC50 = 3.5 ± 1 nM) was around 100-fold more effective than free CN03 (EC50 = 400 ± 5 nM) in reducing rd1 cell death (Fig. 5B). This remarkable increase in efficacy was likely due to CN03’s being encapsulated into GSH-PEG liposomes, because empty liposomes alone had no consistent effect, and free CN03 mixed with empty liposomes was significantly less effective than LP-CN03 (Fig. 5C).

Next, we compared the in vivo bioavailability of CN03 in free form and liposomal formulation after i.v. injection in WT rats, an established standard for pharmacokinetic (PK) studies. The half-life of the free CN03 compound in the blood stream was only about 10 min, presumably because of a rapid excretion of cyclic nucleotides via the renal system (40, 41). Encapsulation of CN03 in liposomes (LP-CN03) prolonged in vivo half-life in the blood stream to more than 24 h (Fig. 5D).

The efficacy of GSH-PEG liposomes for in vivo delivery to the neuroretina was assessed by i.p. administration of liposomes loaded with carboxyfluorescein, followed by in vivo imaging with scanning laser ophthalmoscopy (SLO). Four days after a single i.p. injection, fluorescence was still clearly detectable in the retina (Fig. 5E). In retinal cross-sections carboxyfluorescein strongly labeled choroidal blood vessels, and the retina, especially the outer nuclear layer (ONL), confirming successful delivery of liposomal contents to the photoreceptors (Fig. 5F). We routinely monitored LP-CN03–treated mice and rats in vivo and postmortem (Materials and Methods) but could not find any macroscopic evidence for toxic effects. Likewise, postnatal weight gains during a 2-mo-long LP-CN03 administration were normal in both mice and rats (Fig. S3 A and F).

**Systemic Delivery of LP-CN03 Protects Photoreceptors in Three Murine RD Models in Vivo**. To evaluate in vivo protective effects we administered the LP-CN03 systemically via i.p. injections starting at the respective onset of degeneration in each model and counted the number of photoreceptor rows on ex vivo retinal sections (Fig. 5 G–I and Fig. S3 H and I). In rd1 mice, systemic administration of free CN03 (starting at P10, once per day) had no effect on photoreceptor survival at P14, whereas treatment with LP-CN03 significantly increased photoreceptor numbers (Fig. 5G and Fig. S3G). Also, in the more slowly degenerating rd2 and rd10 models treatment with LP-CN03 (starting at P14, once per day in rd10 and every second day in rd2) resulted in a significant increase in the number of surviving photoreceptor rows, compared with untreated mutant, free CN03, or LP only (Fig. 5 H and I and Fig. S3 H and I). LP-CN03 preserved rd2 retina structurally and functionally at P30 and P60 (Fig. S4). In relative terms, the protection observed was more striking in rd10 animals, which motivated us to evaluate this model in more detail. We analyzed sagittal sections of P30 rd10 retina (Fig. 6A) to survey the number of surviving photoreceptor rows as a function of eccentricity (i.e., distance from the optic nerve).
concentrations may be more relevant for the rd10 ERG responses. In contrast, LP-CN03 strongly protected against prior expectations (22), CN04 and CN05 behaved as substituents, linking the two cGMPS moieties. Dimers CN09 and CN10 with their large-molecular-size R substituent, suggesting that cone function was almost completely preserved in untreated rd10 mice. To investigate this further, we recorded scotopic a-wave activity in rd10 treated animals confirmed that CN03 did not impede cone phototransduction. Across different light intensities, b-wave amplitudes were four- to fivelfold larger in LP-CN03–treated rd10 animals (Fig. 6D and Tables 2 and 3).

A comparison between our data and previously reported ERG recordings from Rho−/− mice (42), in which only cones are functional, suggests that cone function was almost completely preserved in treated rd10 mice. To investigate this further, we recorded scotopic (rod-driven) and photopic (cone-driven) flicker ERGs. As expected for animals with dysfunctional rods (due to Pde6b mutation), scotopic flicker responses in rd10—whether treated or not—were completely abolished (Fig. 6E). Strikingly, photopic flicker responses in LP-CN03–treated animals appeared even larger than in WT (Fig. 6 E and F and Table 3). A likely explanation is that with nonfunctional rd10 rods the cone-driven OFF-bipolar cell channel lacks inhibitory input from the rod pathway, resulting in a higher net cone response to flicker (42). Taken together, our ERG results support evidence that LP-CN03 treatment preserved rd10 cone function through inhibition of rod cell death.

### Discussion

Here, we provide proof of principle that cGMP analogs can counteract photoreceptor degeneration in vivo when delivered across the BRB to their cellular target. We also demonstrate that the preservation of rods can improve the function of cones, lending support to the hypothesis that “sparing the rods” indeed “saves the cones” (4).

Dysregulation of cGMP has been observed in a variety of diseases, including neurodegeneration (34, 43, 44) and RD, where it seems to be a common disease denominator (11). High levels of cGMP likely cause abnormal PKG and/or CNGC activity (17). PKG appears as an important mediator of cGMP-dependent cell death, and its overactivation is known to cause loss of cellular adhesion and a form of cell death reminiscent of anoikis (45, 46). Our data show that PKG inhibition has strong neuroprotective effects on postmitotic photoreceptors, thus corroborating earlier findings on this theme, for instance where reduced PKG activity increased the neuronal tolerance to stress (47). Follow-up studies may shed further light on how PKG inhibition affects downstream processes and how these may promote photoreceptor survival.

With respect to the CNGC, high cGMP levels causing a dangerous inflow of Ca2+ have long since been proposed as a key event in photoreceptor degeneration (29). While recent data indicate that the Ca2+ dynamics rather than the absolute intracellular Ca2+ concentrations may be more relevant for the degeneration of cones in mice (48), there is a general consensus that excessive Ca2+ influx over prolonged periods of time (i.e., in a chronic disease) is detrimental (15, 49). An interesting point for future studies would be to see if cGMP analogs can selectively inhibit any of the rod or cone CNGC subunits.

The fact that cGMP analogs can be tailored to limit the activity of PKG and/or CNGC makes this class of compounds very promising for a targeted therapy of RD. Indeed, we found that CN03 inhibited both PKG and CNGC, probably explaining why this compound performed so well in our test systems. In contrast, and against prior expectations (22), CN04 and CN05 behaved as CNGC activators, suggesting that their large R3 substituents overruled the CNGC inhibitory effect of the R1 + R2 PET substitution. This may also explain the lack of protection by the dimers CN09 and CN10 with their large-molecular-size R3 substituent, linking the two cGMPS moieties.

Another aspect of our study is the administration route of drugs to the retina. In current clinical practice most drugs targeting retinal cells are locally injected into the vitreous body.
where they need to cross the BRB to exert their effects (50). Repeated intraocular injections carry a cumulative risk for serious adverse effects, most notably endophthalmitis (51). Systemic administration can be considered less risky for the eye as well as more patient-friendly. Nevertheless, to avoid any hazards associated with systemic exposure, local application of CN03 to the eye is also a viable option. Besides the delivery as liposomal formulation it may be possible to combine CN03 with alternative drug delivery systems, such as poly(lactic-co-glycolic acid) for intraocular slow release (52) or cyclodextrins for topical delivery (53). Furthermore, the marked prolongation of its in vivo half-life with liposomal encapsulation, and the lack of therapeutic effect without, are in line with previous observations (19, 39) and our findings thus stress the importance of efficient drug delivery for the treatment of retinal diseases. Whether the efficacy of the liposomal formulation stems predominantly from the extension of in vivo half-life or from the improved BRB permeability needs to be addressed in future studies that may use, for instance, in vivo steady-state i.v. dosing. We also propose that our pharmaceutically active compounds for the treatment of RD. The value of this concept for clinical translation is supported by an orphan drug designation for CN03, awarded by the European Medicines Agency (EU/3/15/1462). Moreover, we have adapted a nanoscale liposomal drug delivery vehicle to innovatively and efficiently target the retinal photoreceptors in vivo. Indeed, we demonstrate that drug delivery is a key factor for achieving in vivo therapeutic success. Our approach preserves retinal function in relevant animal models, highlighting its therapeutic potential for genetically diverse and currently untreatable blinding diseases.

### Materials and Methods

For details on the chemical synthesis of cGMP analogs, determination of their lipophilicity, and liposomal encapsulation please refer to SI Materials and Methods. The general work flow for the in vitro and in vivo testing of cGMP analogs is given in Fig. 1. Further details on animals, in vitro cell and retinal explant cultures, Ca²⁺ imaging, in vivo PKs, in vivo imaging and function testing, as well as on statistical analysis are given in SI Materials and Methods. Animals for preparation of primary retinal cell cultures were kept at Centro Servizi Stabulario Interdipartimentale of the University of Modena and Reggio Emilia. The protocol was approved by the Ethical Committee of the University of Modena and Reggio Emilia (protocol no. 106 22/11/2012) and by the Italian Ministero della Salute (346/2015-PR). Animals for in vitro retinal explant studies were kept at the animal facilities of the Biomedical Centre, Lund University. All procedures were evaluated by the local animal care and ethics committees and performed in accordance with permits M172-12, M191-14, and M92-15. Efforts were made to keep the number of

### Table 3. Post hoc analysis using Tukey’s honestly significant difference test on all possible pairwise contrasts for each stimulus condition

| ERG amplitude | Pair               | Mean, μV | SD, μV | CI, μV   | P       |
|---------------|--------------------|----------|--------|---------|---------|
| Scotopic single flash 0.03 | rd10 + LP-CN03 vs rd10 NT | 43.87 | 14.90 | [6.18, 81.56] | 0.0209* |
|               | rd10 + LP-CN03 vs rd10 + LP | 39.98 | 15.42 | [6.06, 78.99] | 0.0440* |
|               | rd10 + LP vs rd10 NT | 3.89 | 15.42 | [−35.12, 42.91] | ns |
| Scotopic single flash 0.3 | rd10 + LP-CN03 vs rd10 NT | 86.78 | 15.60 | [47.32, 126.24] | <0.0001*** |
|               | rd10 + LP-CN03 vs rd10 + LP | 44.70 | 16.15 | [3.86, 85.55] | 0.0305* |
|               | rd10 + LP vs rd10 NT | 42.07 | 16.15 | [1.23, 82.92] | 0.0428* |
| Scotopic single flash 3.0 | rd10 + LP-CN03 vs rd10 NT | 137.00 | 24.27 | [75.59, 198.41] | <0.0001*** |
|               | rd10 + LP-CN03 vs rd10 + LP | 86.83 | 25.13 | [23.26, 150.39] | 0.0067** |
|               | rd10 + LP vs rd10 NT | 50.17 | 25.13 | [−13.39, 113.74] | ns |
| Scotopic single flash 30 | rd10 NT vs rd10 + LP-CN03 | 15.03 | 6.33 | [−1.11, 31.18] | ns |
| a-wave        | rd10 NT vs rd10 + LP-CN03 | 18.54 | 5.55 | [4.38, 32.70] | 0.0097** |
|               | rd10 NT vs rd10 + LP-CN03 | 15.03 | 6.33 | [−1.11, 31.18] | ns |
| b-wave        | rd10 NT vs rd10 + LP-CN03 | 3.51 | 6.33 | [−12.64, 19.65] | ns |
|               | rd10 NT vs rd10 + LP-CN03 | 163.44 | 31.07 | [84.85, 242.04] | 0.0001*** |
|               | rd10 NT vs rd10 + LP-CN03 | 139.45 | 32.16 | [58.10, 220.81] | 0.0009** |
|               | rd10 NT vs rd10 + LP-CN03 | 23.99 | 32.16 | [−57.36, 105.35] | ns |
| Scotopic 5-Hz flicker | rd10 NT vs rd10 + LP-CN03 | 87.35 | 3.04 | [79.08, 95.62] | <0.0001*** |
|               | rd10 NT vs rd10 + LP-CN03 | 86.92 | 2.82 | [79.27, 94.58] | 0.0001*** |
|               | rd10 NT vs rd10 + LP-CN03 | 86.17 | 3.04 | [77.91, 94.44] | <0.0001*** |
| Photopic 10-Hz flicker | rd10 NT vs rd10 + LP-CN03 | 43.75 | 3.04 | [35.45, 52.05] | <0.0001*** |
|               | rd10 NT vs rd10 + LP-CN03 | 32.32 | 5.21 | [18.03, 46.61] | 0.0029** |
|               | rd10 NT vs rd10 + LP-CN03 | 21.15 | 5.88 | [5.02, 37.27] | 0.0068** |
|               | rd10 NT vs rd10 + LP-CN03 | 6.51 | 6.16 | [−10.40, 23.42] | ns |

ns: P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; LP, empty liposome; NT, not treated.
animals used and suffering from a minimum. Animals for in vivo studies were kept in the Tübingen Institute for Ophthalmic Research animal housing facility. All in vivo procedures were performed in accordance with the local ethics committee at Tübingen University ($4$ registrations from $29$ to $04-10$; $30-06-10$; $11-03-11$; animal permit AKS/12) and the Association for Research in Vision and Ophthalmology statement for the use of animals in ophthalmic and visual research.

1. Berger W, Kloeckener-Gruissem B, Neidhardt J (2010) The molecular basis of human retinal and vitreoretinal diseases. *Prog Retin Eye Res* 29:335–375.
2. Sahel JA, Marazova K, Audio J (2014) Clinical characteristics and current therapies for inherited retinal degenerations. *Cold Spring Harb Perspect Med* 5:a017111.
3. Kennan A, Aheme A, Humphries P (2005) Light in retinits pigmentosa. *Trends Genet* 21:103–110.
4. Cuccio CA, Osxlcy C, Jackson GR (2000) Spare the rods, save the cones in aging and age-related maculopathy. *Invest Ophthalmol Vis Sci* 41:2015–2018.
5. Lucas KA, et al. (2000) Gylcyl cyclases and signaling by cyclic GMP. *Pharmacol Rev* 52:375–414.
6. Farber DB, Loeilley RN (1974) Cyclic guanosine monophosphate: Elevation in degenerating photoreceptor cells of the C3H mouse retina. Science 186:449–451.
7. Paquet-Durand F, Hauck SM, van Veen T, Ueffing M, Ekström P (2009) PKG activity causes photoreceptor cell death in two retinits pigmentosa models. *J Neurochem* 108:796–810.
8. 18:882 www.pnas.org/cgi/doi/10.1073/pnas.1718792115
9. 116:3110
10. 395:710
11. Vighi et al. *J Chem Neuroanat*
12. 2014-2015:21. Butt E, Pöhler D, Genieser HG, Huggins JP, Bucher B (1995) Inhibition of cyclic GMP-dependent protein kinase mediated effects by (Rp)-8-bromo-PET-cyclic GMPS. *Biochemistry* 34:9341–9350.
13. Iribarne M, Masai I (2017) Neurotoxicity of cGMP in the vertebrate retina: From the apoptosis link. *J Neurogenet* 88:106–118.
14. Paquet-Durand F, et al. (2011) A key role for cyclic nucleotide gated (CNG) channels in inherited retinal degenerations. *Hum Mol Genet* 20:5133–5143.
15. Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: The calcium-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS. *Biochemistry* 34:9341–9350.
16. 32:2639–2646.
17. Wang T, Tsang SH, Chen J (2017) Two pathways of rod photoreceptor cell death induced by elevated cGMP. *Hum Mol Genet* 26:2299–2306.
18. Campbell M, et al. (2011) Systemic low-molecular weight drug delivery to pre-selected neuronal regions. *EMBO Mol Med* 3:235–245.
19. Rip J, et al. (2014) Glutathione PEGylated liposomes: Pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. *J Drug Target* 22:460–467.
20. Butt E, Eigenthaler M, Genieser HG (1994) (Rp)-8-PCP-cGMP, a novel cGMP-dependent protein kinase inhibitor. *Eur J Pharmacol* 269:265–268.
21. Butt E, Pöhler D, Genieser HG, Huggins JP, Buecher B (1995) Inhibition of cyclic GMP-dependent protein kinases mediated effects by (Rp)-8-bromo-PET-cyclic GMPS. *Br J Pharmacol* 116:3110–3116.
22. Wei JY, Cohen ED, Van YY, Genieser HG, Barnstable CJ (1996) Identification of competitive antagonists of the rod photoreceptor cGMP-gated cation channel: Betaephin-1,3-etheno-substituted cGMP analogues as probes of the GMP-binding site. *Biochemistry* 35:16815–16823.
23. Kramer RH, Tibbs GR (1996) Antagonists of cyclic nucleotide-gated channels and molecular mapping of their site of action. *J Neurosci* 16:1285–1293.
24. Kramer RH, Karpen JW (1998) Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. *Nature* 395:710–713.
25. Demontis GC, Aruta C, Comitato A, De Marzo A, Marigo V (2012) Functional and molecular characterization of rod-like cells from retinal stem cells derived from the adult ciliary epithelium. *PLoS One* 7:e32339.
26. Caffe AR, et al. (2001) Mouse retina explants after long-term culture in serum free medium. *J Chem Neuroanat* 22:263–273.
27. Wei T, et al. (2012) Light-driven calcium signals in mouse cone photoreceptors. *J Neurosci* 32:6581–6594.
28. Kulkarni M, et al. (2015) Imaging Ca2+ dynamics in cone photoreceptor axon terminals of the mouse retina. *J Vis Exp* e52588.

**ACKNOWLEDGMENTS.** We thank Hodan Abdissh, Ursula Havemann, Dilek Imren, Stefanie Lorenz, Undine Manzau, Klaudia Masarini, Antonella Mauro, Flavia Parise, Chiara Paolinni, Norman Rieger, and Birgitta Sandström for excellent technical assistance; Janett Hoogstrate, Arto Urtti, and Christina Fasser for helpful discussions; Eberhart Zrenner, Christer Säfholm, and Bernd Wissinger for technical advice and discussions; and Mathias Seeiger for advice on ERG data analysis.